Cosmos Health Forecasts Over $2.5M Annual Cur18 US Revenue Within 18 Months
Cosmos Health projects Cur18™ to generate over $2.5 million in incremental annual revenue in the United States within the next 12 to 18 months, driven by direct-to-consumer e-commerce channels. The phased strategy plans an eventual expansion into selected retail outlets based on pricing, sales volume assumptions, and distribution scaling.
1. Cur18 Revenue Projection
Cosmos Health expects Cur18™ to generate over $2.5 million in incremental annual revenue in the US within 12 to 18 months, reflecting internal assumptions on pricing, expected sales volumes, and distribution expansion.
2. Phased Commercialization Strategy
The company plans a phased market entry, initially focusing on direct-to-consumer e-commerce channels, with potential expansion into selected retail outlets as distribution and brand awareness grow.
3. Product Profile and Validation
Cur18™ is a curcumin-based dietary supplement formulated with a proprietary ingredient evaluated in published pharmacokinetic and clinical studies and positioned within the US turmeric/curcumin supplement category.
4. Corporate Background
Cosmos Health is a diversified, vertically integrated healthcare group with proprietary pharmaceutical and nutraceutical brands, EU GMP manufacturing capabilities, R&D partnerships in major health disorders, and a telehealth business through its ZipDoctor subsidiary.